All Stories

  1. Is autism a developmental zinc deficiency?
  2. Targeting Platelet Activating Factor Signaling for Therapeutic Benefits in Neurodegenerative Disorders
  3. Metal Dyshomeostasis as a Driver of Gut Pathology in Autism Spectrum Disorders
  4. Application of Human Plasma Targeted Lipidomics and Analysis of Toxic Elements to Capture the Metabolic Complexities of Hypothyroidism
  5. Zinc signaling controls astrocyte‐dependent synapse modulation via the PAF receptor pathway
  6. Neuroprotective Benefits of Rosmarinus officinalis and Its Bioactives against Alzheimer’s and Parkinson’s Diseases
  7. Polar lipids modify Alzheimer’s Disease pathology by reducing astrocyte pro-inflammatory signaling through platelet-activating factor receptor (PTAFR) modulation
  8. Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer’s Disease Pathology
  9. The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome—Plant Metabolites in IBS Treatment
  10. Consensus recommendations on chewing, swallowing and gastrointestinal problems in Phelan-McDermid syndrome
  11. Dissecting the 22q13 region to explore the genetic and phenotypic diversity of patients with Phelan-McDermid syndrome
  12. The use of organoids in food research
  13. The Rationale for Vitamin, Mineral, and Cofactor Treatment in the Precision Medical Care of Autism Spectrum Disorder
  14. Editorial: Interactions of the nervous system with bacteria, volume II
  15. Identification of Nanoparticle Properties for Optimal Drug Delivery across a Physiological Cell Barrier
  16. Metal Profiles in Autism Spectrum Disorders: A Crosstalk between Toxic and Essential Metals
  17. The Role of Dietary Lipids in Cognitive Health: Implications for Neurodegenerative Disease
  18. Identification of the common neurobiological process disturbed in genetic and non-genetic models for autism spectrum disorders
  19. Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients
  20. Non-Genetic Modifiers of Synaptic Plasticity and Neurotransmission in the Central Nervous System (CNS) in Health and Disease
  21. Prevalence of low dietary zinc intake in women and pregnant women in Ireland
  22. Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments
  23. Atherosclerosis fate in the era of tailored functional foods: Evidence-based guidelines elicited from structure- and ligand-based approaches
  24. Prenatal Zinc Deficient Mice as a Model for Autism Spectrum Disorders
  25. Anti-inflammatory and antioxidant activities of polar lipids in vitro and implications for neurodegenerative disease
  26. Zinc is a key regulator of gastrointestinal development, microbiota composition and inflammation with relevance for autism spectrum disorders
  27. Localizing Therapeutics to the Brain
  28. S100B dysregulation during brain development affects synaptic SHANK protein networks via alteration of zinc homeostasis
  29. Autism Spectrum Disorders
  30. Autism Spectrum Disorders: Etiology and Pathology
  31. The Metallome as a Link Between the “Omes” in Autism Spectrum Disorders
  32. Expression Analysis of Zinc Transporters in Nervous Tissue Cells Reveals Neuronal and Synaptic Localization of ZIP4
  33. Editorial: Interactions of the Nervous System With Bacteria
  34. Sperm selection by rheotaxis improves sperm quality and early embryo development
  35. Activation of the medial preoptic area (MPOA) ameliorates loss of maternal behavior in a Shank2 mouse model for autism
  36. Altered gut–brain signaling in autism spectrum disorders—from biomarkers to possible intervention strategies
  37. IPSC-derived intestinal organoids and current 3D intestinal scaffolds
  38. Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer’s Disease
  39. Rho GTPases in the Amygdala—A Switch for Fears?
  40. Comparing nanoparticles for drug delivery: The effect of physiological dispersion media on nanoparticle properties
  41. Concentrations of Essential Trace Metals in the Brain of Animal Species—A Comparative Study
  42. Autism-associated SHANK3 mutations impair maturation of neuromuscular junctions and striated muscles
  43. Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
  44. Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers
  45. Metals and amyloid gain-of-toxic mechanisms in neurodegenerative diseases
  46. Metallic-based nanocarriers: methods employed in nanoparticle characterization and assessing the interaction with the blood–brain barrier
  47. Biometals and nutrition in autism spectrum disorders
  48. Measuring biometals
  49. Extracerebral biometals in autism spectrum disorders: the gut–brain axis
  50. Biometals in Autism Spectrum Disorders
  51. Introduction to metallomics: the science of biometals
  52. Human stem cell models linking biometal abnormalities and autism
  53. Animal models for trace metal abnormalities—links to autism
  54. Linking trace metal abnormalities to autism—insights from epidemiological studies
  55. The history of metals in autism spectrum disorders
  56. The specific role of zinc in autism spectrum disorders
  57. Biometal homeostasis as a therapeutic strategy in autism spectrum disorders
  58. Future perspectives: autism, a disorder of biometal imbalance?
  59. Nonessential metals and their brain pathology
  60. Animal models for autism—links to biometal abnormalities
  61. Essential trace metals and their function in brain development
  62. Zinc Deficiency During Pregnancy Leads to Altered Microbiome and Elevated Inflammatory Markers in Mice
  63. The Role of Trace Metals in Alzheimer’s Disease
  64. Nanomedicine Against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
  65. ROS-responsive “smart” polymeric conjugate: Synthesis, characterization and proof-of-concept study
  66. Distribution and Relative Abundance of S100 Proteins in the Brain of the APP23 Alzheimer’s Disease Model Mice
  67. Altered Intestinal Morphology and Microbiota Composition in the Autism Spectrum Disorders Associated SHANK3 Mouse Model
  68. Shank3 Transgenic and Prenatal Zinc-Deficient Autism Mouse Models Show Convergent and Individual Alterations of Brain Structures in MRI
  69. Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives
  70. Prospects of Zinc Supplementation in Autism Spectrum Disorders and Shankopathies Such as Phelan McDermid Syndrome
  71. Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain
  72. Zinc Binding to S100B Affords Regulation of Trace Metal Homeostasis and Excitotoxicity in the Brain
  73. Brain Lateralization in Mice Is Associated with Zinc Signaling and Altered in Prenatal Zinc Deficient Mice That Display Features of Autism Spectrum Disorder
  74. Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer’s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery
  75. De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability
  76. Corrigendum to: EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION (International Journal of Pharmaceutics. 511 (1) (2016) 331-340)
  77. Characterization of zinc amino acid complexes for zinc delivery in vitro using Caco-2 cells and enterocytes from hiPSC
  78. Nanomedicine and Neurodegenerative Diseases: An Introduction to Pathology and Drug Targets
  79. Object Phobia and Altered RhoA Signaling in Amygdala of Mice Lacking RICH2
  80. Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates
  81. Zinc deficiency and low enterocyte zinc transporter expression in human patients with autism related mutations in SHANK3
  82. Molecular and Cellular Mechanisms of Synaptopathies
  83. Zinc in Autism
  84. Extracerebral Dysfunction in Animal Models of Autism Spectrum Disorder
  85. EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION
  86. Zinc Deficiency
  87. Activity and circadian rhythm influence synaptic Shank3 protein levels in mice
  88. The Shank3 Interaction Partner ProSAPiP1 Regulates Postsynaptic SPAR Levels and the Maturation of Dendritic Spines in Hippocampal Neurons
  89. Enlarged dendritic spines and pronounced neophobia in mice lacking the PSD protein RICH2
  90. Gender Dependent Evaluation of Autism like Behavior in Mice Exposed to Prenatal Zinc Deficiency
  91. Nanoparticle transport across the blood brain barrier
  92. Cellular Zinc Homeostasis Contributes to Neuronal Differentiation in Human Induced Pluripotent Stem Cells
  93. Actin-Dependent Alterations of Dendritic Spine Morphology in Shankopathies
  94. Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
  95. Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
  96. Behavioral impairments in animal models for zinc deficiency
  97. N-cadherin-mediated cell adhesion is regulated by extracellular Zn2+
  98. Effects of Trace Metal Profiles Characteristic for Autism on Synapses in Cultured Neurons
  99. Zinc in Gut-Brain Interaction in Autism and Neurological Disorders
  100. Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release
  101. Loss of COMMD1 and copper overload disrupt zinc homeostasis and influence an autism-associated pathway at glutamatergic synapses
  102. The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation
  103. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport
  104. Characterization of biometal profiles in neurological disorders
  105. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution
  106. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders
  107. A role for synaptic zinc in ProSAP/Shank PSD scaffold malformation in autism spectrum disorders
  108. Environmental Factors in Autism
  109. Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems
  110. The Nedd4-binding protein 3 (N4BP3) is crucial for axonal and dendritic branching in developing neurons
  111. Autism-Associated Mutations in ProSAP2/Shank3 Impair Synaptic Transmission and Neurexin-Neuroligin-Mediated Transsynaptic Signaling
  112. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2
  113. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies
  114. Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
  115. Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
  116. Development of Novel Zn2+ Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences
  117. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation
  118. Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold
  119. Rare Feeding Behavior of Great-Tailed Grackles (Quiscalus mexicanus) in the Extreme Habitat of Death Valley~!2010-01-08~!2010-03-08~!2010-05-21~!
  120. Abstract 3480: XIAP inhibitors prime glioblastoma cells for γ-irradiation-induced apoptosis and circumvent radioresistance of glioblastoma stem cells
  121. Synaptogenesis of hippocampal neurons in primary cell culture
  122. Synaptic Cross-talk betweenN-Methyl-d-aspartate Receptors and LAPSER1-β-Catenin at Excitatory Synapses
  123. Small-Molecule XIAP Inhibitors Enhance γ-Irradiation-Induced Apoptosis in Glioblastoma
  124. Efficient targeting of proteins to post-synaptic densities of excitatory synapses using a novel pSDTarget vector system